Australia markets closed

Replimune Group Inc (7R8.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
7.40+0.10 (+1.37%)
At close: 08:02AM CET
Full screen
Previous close7.30
Open7.40
Bid7.45 x 0
Ask8.00 x 0
Day's range7.40 - 7.40
52-week range5.35 - 21.80
Volume0
Avg. volume0
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date16 May 2024 - 20 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

    Philip Astley-Sparke to transition from current role of CEO to Executive Chairman Planned leadership changes position the Company for commercialization Preparations on track to submit RP1 biologics license application (BLA) in 2H 2024 WOBURN, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced changes to its executive leadership team designe

  • Zacks

    How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%

    The average of price targets set by Wall Street analysts indicates a potential upside of 50.2% in Replimune Group, Inc. (REPL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

  • Zacks

    What Makes Replimune Group, Inc. (REPL) a New Buy Stock

    Replimune Group, Inc. (REPL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.